智通财经APP讯，中国再生医学(08158)公布，黄宝田先生因其他个人事务已辞任及将不再为公司的首席财务官、公司秘书及香港联合交易所有限公司GEM证券上市规则第5.24条项下的公司授权代表、根据公司条例(香港法例第622章)第16部及GEM上市规则第24.05(2)条代表公司在香港接收法律程序文件与通知的授权代表，自2025年4月25日起生效。
同日起，雒敏女士将获委任为公司非执行董事;严仕斌先生将获委任为公司首席财务官。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.